SAN FRANCISCO—Serial measurements of cardiac troponin using an investigational high-sensitivity assay enhanced risk stratification for cardiovascular disease and heart failure in patients with stable ischemic heart disease, according to an analysis of the PROVE IT-TIMI 22 study, presented March 9 at the American College of Cardiology’s (ACC) scientific session.
Cardiac troponin is an emerging prognostic biomarker in patients with stable ischemic heart disease. In this study, lead investigator Ryan G. O'Malley, MD, of Brigham and Women's Hospital in Boston, and colleagues assessed the prognostic performance of serial measurements of an investigational high-sensitivity cardiac troponin assay in patients with stable ischemic heart disease.
About the lead author:
Dr. O'Malley is in the internal medicine/adult primary care department of Brigham and Women's Hospital in Boston.